Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Brink

Showing results (1-10 of 215) with videos related to

Pageof 22
Sort By:
Current Drug Targets|November 27, 2002
Are gap junction channels a therapeutic target and if so what properties are best exploited?Peter R Brink
Plastic and Reconstructive Surgery|October 1, 1990
Evaluating breast parenchymal maldistribution with regard to mastopexy and augmentation mammaplastyR R Brink
Plastic and Reconstructive Surgery|April 1, 1993
Management of true ptosis of the breastR R Brink
Acta Physiologica Scandinavica|January 15, 1999
Gap junctions in vascular smooth muscleP R Brink
Plastic and Reconstructive Surgery|November 8, 2001
Auricular displacement with rhytidectomyR R Brink
Plastic and Reconstructive Surgery|September 1, 1996
Sequestered fluid and breast implant malpositionR R Brink
The Journal of Membrane Biology|January 1, 1983
Effect of deuterium oxide on junctional membrane channel permeabilityP R Brink
Clinical and Experimental Pharmacology & Physiology|December 1, 1996
Gap junction channel gating and permselectivity: their roles in co-ordinated tissue functionP R Brink
Cell Death and Differentiation|August 15, 2009
Regulation of TNFRSF and innate immune signalling complexes by TRAFs and cIAPsJ Silke, R Brink
The Journal of Biological Chemistry|March 28, 1998
Tumor necrosis factor receptor (TNFR)-associated factor 2A (TRAF2A), a TRAF2 splice variant with an extended RING finger domain that inhibits TNFR2-mediated NF-kappaB activationR Brink, H F Lodish
Pageof 22

Showing results (1-10 of 215) with videos related to

Sort By:
Pageof 22
Current Drug Targets|November 27, 2002
Are gap junction channels a therapeutic target and if so what properties are best exploited?Peter R Brink
Plastic and Reconstructive Surgery|October 1, 1990
Evaluating breast parenchymal maldistribution with regard to mastopexy and augmentation mammaplastyR R Brink
Plastic and Reconstructive Surgery|April 1, 1993
Management of true ptosis of the breastR R Brink
Acta Physiologica Scandinavica|January 15, 1999
Gap junctions in vascular smooth muscleP R Brink
Plastic and Reconstructive Surgery|November 8, 2001
Auricular displacement with rhytidectomyR R Brink
Plastic and Reconstructive Surgery|September 1, 1996
Sequestered fluid and breast implant malpositionR R Brink
The Journal of Membrane Biology|January 1, 1983
Effect of deuterium oxide on junctional membrane channel permeabilityP R Brink
Clinical and Experimental Pharmacology & Physiology|December 1, 1996
Gap junction channel gating and permselectivity: their roles in co-ordinated tissue functionP R Brink
Cell Death and Differentiation|August 15, 2009
Regulation of TNFRSF and innate immune signalling complexes by TRAFs and cIAPsJ Silke, R Brink
The Journal of Biological Chemistry|March 28, 1998
Tumor necrosis factor receptor (TNFR)-associated factor 2A (TRAF2A), a TRAF2 splice variant with an extended RING finger domain that inhibits TNFR2-mediated NF-kappaB activationR Brink, H F Lodish
Pageof 22